Budget impact of endovascular treatment for acute ischaemic stroke patients in the Netherlands for 2015-2021

IntroductionEndovascular treatment (EVT) has been proven to be both effective and cost-effective for patients with acute ischaemic stroke. We investigated the budget impact of large-scale implementation of EVT for acute ischaemic stroke patients in the Netherlands for 2015-2021.MethodsAn analysis was performed from a healthcare perspective as a preplanned substudy of the Multicenter Randomized Clinical trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN). Estimated yearly costs during follow-up after stroke for patients who had or had not been treated with EVT as add-on to usual care were linked to numbers of new patients retrieved from 2 Dutch registries of EVT that started after the last inclusion in MR CLEAN (2014). Aggregated costs and costs per care sector were calculated based on prevalence using a population dynamic tool.ResultsFrom 2015, the yearly number of new acute ischaemic stroke patients receiving EVT increased almost threefold, from 812 in 2015 to 2,370 in 2021. The introduction of EVT plus usual care resulted in estimated net annual savings that increased from euro 2.9 million in 2015 to euro 58 million in 2021.ConclusionOffering EVT as add-on to usual care for acute ischaemic stroke patients was increasingly cost saving from a national healthcare perspective but affected distinct healthcare sectors differently.

Automated summary

A study in the Netherlands found that endovascular treatment (EVT) is effective and cost-effective for patients with acute ischemic stroke. The study also revealed that the number of acute ischemic stroke patients receiving EVT has increased significantly from 2015 to 2021, leading to cost savings in healthcare.